Brian Lortie, president and CEO at Uniquity Bio, offered up key insights on building teams, securing capital, and operating with efficiency during a recent Business of Biotech podcast recording.
- Why Empathy Is Your Most Powerful Leadership Tool
- Essential Medicines And The Need For A Robust U.S. Supply Chain
- Navigating Tariffs: Implications And Strategies For Pharmaceuticals Manufacturers
- Borrowed Brilliance: Is Pharma Becoming Overly Reliant On Acquisitions?
- Securing Capital At The Right Moment: How Much Should Startups Ask For?
- How HHS Budget Cuts And Vaccine Hesitancy Threaten Clinical Trial Operations — And What Leaders Can Do
- Understanding Re-Narcotization Is Key To Battling Opioids Like Fentanyl
- Amgen's Ian Thompson On Leadership And A Global Mindset
COMPANIES TO WATCH
-
![Stacy Lindborg_Imunon]( "Companies To Watch: Imunon")
Companies To Watch: ImunonImunon aims to shake up the standard of care in the frontline treatment of advanced ovarian cancer.
-
![Tim Lu_Senti Bio]( "Companies To Watch: Senti Bio")
Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.
-
![Amy Burroughs_Terns Pharmaceuticals]( "Companies To Watch: Terns Pharmaceuticals")
Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.
-
![Dr-Stella-Sarraf_Spinogenix]( "Companies To Watch: Spinogenix")
Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.
WHERE ARE THEY NOW
-
![Bobak Azamian]( "Where Are They Now? Tarsus Pharmaceuticals")
Where Are They Now? Tarsus PharmaceuticalsTarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.
-
![Teva Cover]( "Where Are They Now? Teva Pharmaceuticals")
Where Are They Now? Teva PharmaceuticalsTeva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.
-
![Ironwood Cover_2016]( "Where Are They Now? Ironwood Pharmaceuticals")
Where Are They Now? Ironwood PharmaceuticalsIronwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
NEWSLETTER ARCHIVE
- 04.30.25 -- How Much Should Startups Ask For?
- 04.28.25 -- Understanding Re-Narcotization Is Key To Battling Opioids Like Fentanyl
- 04.25.25 -- Amgen's Ian Thompson On Leadership And A Global Mindset
- 04.24.25 -- Accelerating Bioprocessing: Smarter DSP, Analytics, And Scale-Up
- 04.24.25 -- Clinical Data Like You've Never Seen it Before
SPOTLIGHT
Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the recent sunset of the FDA's rare pediatric disease Priority Review Voucher program.
